An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir

BACKGROUND: The World Health Organisation approved boosted atazanavir as a preferred second line protease inhibitor in 2010. This is as an alternative to the current boosted lopinavir. Atazanavir has a lower genetic barrier than lopinavir. We compared the virological outcomes of patients during the...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:BMC Infect Dis
Main Authors: Laker, Eva Agnes Odongpiny, Nabaggala, Maria Sarah, Kaimal, Arvind, Nalwanga, Damalie, Castelnuovo, Barbara, Musubire, Abdu, Kiragga, Agnes, Lamorde, Mohammed, Ratanshi, Rosalind Parkes-
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2019
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6434787/
https://ncbi.nlm.nih.gov/pubmed/30909871
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12879-019-3907-5
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki